var data={"title":"Labetalol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Labetalol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6425?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=labetalol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Labetalol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=labetalol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Labetalol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186205\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Trandate [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186206\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Trandate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186247\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihypertensive;</li>\n      <li>\n        Beta-Blocker With Alpha-Blocking Activity</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186209\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b>\n      <i> Oral:</i> Initial: 100 mg twice daily, may increase as needed every 2 to 3 days by 100 mg twice daily (titration increments not to exceed 200 mg twice daily) until desired response is obtained; usual dosage range (ASH/ISH [Weber 2014]): 100 to 300 mg twice daily; may require up to 2,400 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute hypertension (hypertensive emergency/urgency):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i> Initial: 10 to 20 mg IV push over 2 minutes; may administer additional injections using double the dose (maximum dose: 80 mg/dose) at 10-minute intervals until target SBP is reached; total maximum dose: 300 mg. May consider a continuous infusion (MacCarthy 1983; Marik 2011; Sarafidis 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuous IV infusion:</i> Initial: 0.5 to 2 mg/minute (Sarafidis 2012; Marik 2007). Some patients may require doses within the range of 2 to 10 mg/minute (Marik 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>Although loading infusions are well described in the product labeling, the labeling is silent in specific clinical situations, such as in the patient who has an initial response to labetalol infusions but cannot be converted to an oral route for subsequent dosing. There is limited documentation of prolonged continuous infusions (ie, &gt;300 mg/day). In rare clinical situations, higher continuous infusion doses up to 6 mg/minute have been used in the critical care setting (eg, aortic dissection) and up to 8 mg/minute (eg, hypertension with ongoing acute ischemic stroke). At these doses, it may be best to consider an alternative agent if the labetalol infusion is not meeting the goals of therapy. At the other extreme, continuous infusions at relatively low doses (0.03 to 0.1 mg/minute) have been used in some settings (following loading infusion in patients who are unable to be converted to oral regimens or in some cases as a continuation of outpatient oral regimens). These prolonged infusions should not be confused with loading infusions. Because of wide variation in the use of infusions, an awareness of institutional policies and practices is extremely important. Careful clarification of orders and specific infusion rates/units is required to avoid confusion. Due to the prolonged duration of action, careful monitoring should be extended for the duration of the infusion and for several hours after the infusion. Excessive administration may result in prolonged hypotension and/or bradycardia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Arterial hypertension in acute ischemic stroke (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patient otherwise eligible for reperfusion treatment (eg, alteplase) except blood pressure (BP) &gt;185/110 mm Hg:</i> 10 to 20 mg over 1 to 2 minutes; may repeat once. If BP does not decline and remains &gt;185/110 mm Hg, alteplase should not be administered (AHA/ASA [Jauch 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Management of BP during and after reperfusion treatment (eg, alteplase) to maintain BP &le;180/105 mm Hg:</i> If systolic BP &gt;180 to 230 mm Hg or diastolic &gt;105 to 120 mm Hg, then administer 10 mg over 1 to 2 minutes followed by an infusion of 2 to 8 mg/minute. If hypertension is refractory or diastolic BP &gt;140 mm Hg, consider other IV antihypertensives (eg, nitroprusside) (AHA/ASA [Jauch 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Arterial hypertension in intracranial hemorrhage (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i> Initial: 5 to 20 mg IV push over 2 minutes; may administer additional doses every 15 minutes until target SBP is reached; total maximum dose: 300 mg (AHA/ASA [Broderick 2007]). Some have suggested initial doses in the range of 20 to 80 mg administered every 10 minutes (Rose 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuous IV infusion:</i> Initial: 0.5 to 2 mg/minute (AHA/ASA [Broderick 2007]; Mocco 2006; Ortega-Gutierrez 2013; Rose 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertensive emergency in pregnancy (systolic BP &ge;160 mm Hg or diastolic BP &ge;110 mm Hg) (off-label dose):</b>\n      <i> IV:</i> Initial: 20 mg; if blood pressure still exceeds thresholds, may increase dose every 10 minutes in increments of 20 to 40 mg to a maximum single dose of 80 mg (Refer to administration protocols developed by the American College of Obstetricians and Gynecologists; ACOG 2015). A maximum total cumulative dose of 300 mg is recommended (Magee 2014). <b>Note:</b> After the initial dose, may initiate a continuous infusion of 1 to 2 mg/minute instead of intermittent dosing (Magee 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Subarachnoid hemorrhage (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV bolus:</i> Initial: 5 to 40 mg (Liu-DeRyke 2008; Patel 1993; Woloszyn 2012). Some have recommended 20 to 80 mg every 10 minutes up to a maximum of 300 mg followed by a continuous IV infusion (Mocco 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV infusion:</i> 0.5 to 2 mg/minute; based on very limited information (Mocco 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV to oral conversion: </b>Upon discontinuation of IV infusion, may initiate oral dose of 200 mg followed in 6 to 12 hours with an additional dose of 200 to 400 mg. Thereafter, dose patients with 400 to 2,400 mg/day in divided doses depending on blood pressure response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186227\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=labetalol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Labetalol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Use care with labetalol continuous IV infusions; the rate of administration is different for pediatric patients (mg/kg/hour) versus adult patients (mg/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hypertension (off-label):</b> Children and Adolescents: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> Initial: 1 to 3 mg/kg/day, in 2 divided doses; maximum daily dose: 10 to 12 mg/kg/day, up to 1,200 mg/day (NHLBI 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV (intermittent bolus):</i> 0.2 to 1 mg/kg/dose; maximum dose: 40 mg; use should be reserved for severe hypertension (NHBPEP 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertensive emergency:</b> Infants, Children, and Adolescents: <i>Continuous IV infusion: </i>0.25 to 3 mg/kg/<b>hour</b>; initiate at lower end of range and titrate up slowly (NHBPEP 2004). One retrospective study in infants and children &le;24 months of age observed reductions in blood pressure at doses up to 0.59 mg/kg/<b>hour</b> with little additional benefit at higher doses (Thomas 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186210\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Initial: 100 mg twice daily; may titrate in increments of 100 mg twice daily; usual maintenance: 100 to 200 mg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ACCF/AHA Expert Consensus recommendations: Consider lower initial doses and titrating to response (Aronow, 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186211\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186212\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, dosage reduction may be necessary in hepatic impairment due to decreased metabolism and increased oral bioavailability, use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186176\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (4 mL, 20 mL, 40 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/5 mL (5 mL); 50 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trandate: 100 mg [DSC], 200 mg [DSC], 300 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 200 mg, 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186160\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186180\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer without regard to food; however, the absolute bioavailability of labetalol is increased when administered with food. Administer in a consistent manner with regards to meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Bolus dose may be administered IV push at a rate of 10 mg/minute; may follow with continuous IV infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472668\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 200 mg in 200 mL (concentration: 1 mg/mL) <b>or </b>500 mg in 250 mL (concentration: 2 mg/mL) of D5W</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472669\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 1 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186179\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypertension:</b> Management of hypertension (IV indicated for severe hypertension only [eg, hypertensive emergencies])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients (JNC8 [James, 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;60 years of age, with systolic blood pressure (SBP) &ge;150 mm Hg or diastolic blood pressure (DBP) &ge;90 mm Hg. Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &lt;60 years of age, with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull;  Patients &ge;18 years of age with diabetes, with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 years of age with chronic kidney disease (CKD), with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In patients with CKD, regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker <b>instead of</b> an ACEI or ARB.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726710\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hypertensive emergency in pregnancy; Subarachnoid hemorrhage; Hypertension during acute ischemic stroke; Pediatric hypertension; Chronic hypertension in pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186256\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Labetalol may be confused with betaxolol, lamoTRIgine, Lipitor</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Normodyne may be confused with Norpramin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Trandate may be confused with traMADol, TRENtal</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186167\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Orthostatic hypotension (intravenous: &le;58%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (1% to 20%), fatigue (1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;19%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (1% to 5%), edema (&le;2%), flushing (1%), ventricular arrhythmia (intravenous: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Paresthesia (&le;7%; includes tingling of the scalp), drowsiness (3%), headache (2%), vertigo (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (&le;4%), pruritus (1%), skin rash (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (&le;4%), vomiting (&le;3%), dysgeusia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Ejaculatory failure (&le;5%), impotence (1% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (&le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal congestion (1% to 6%), dyspnea (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, angioedema, bradycardia, bronchospasm, cardiac failure, cholestatic jaundice, diabetes insipidus, heart block, hepatic necrosis, hepatitis, hypersensitivity reaction, myopathy, Peyronie's disease, positive ANA titer, psoriasiform eruption, Raynaud's phenomenon, syncope, systemic lupus erythematosus, transient alopecia, urinary retention, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186184\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to labetalol or any component of the formulation; severe bradycardia; heart block greater than first degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; bronchial asthma or a history of obstructive airway disease; uncompensated cardiac failure; conditions associated with severe and prolonged hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for alpha/beta adrenergic blocking agents is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186164\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were treated with alpha<sub>1</sub>-blockers. There appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic injury: Severe hepatocellular injury has been reported (rare). The hepatic injury is usually reversible, but hepatic necrosis and death have been reported. Injury has occurred after both short- and long-term treatment and may be slowly progressive despite minimal symptomatology. Periodically monitor LFTs. If liver injury or jaundice occurs, discontinue labetalol and do not restart.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension/syncope: Symptomatic hypotension with or without syncope may occur with labetalol; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Initiation with a low dose and gradual up-titration may help to decrease the occurrence of hypotension or syncope. Advise patients to avoid driving or other hazardous tasks during initiation of therapy due to the risk of syncope. Orthostatic hypotension may occur with IV administration; patient should remain supine during and for up to 3 hours after IV administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms. May also reduce release of insulin in response to hyperglycemia; dosage of antidiabetic agents may need to be adjusted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure (HF): Use with extreme caution in patients with compensated heart failure and monitor for a worsening of the condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; bioavailability is increased due to decreased first-pass metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use beta blockers with caution in patients with myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral vascular disease (PVD) and Raynaud disease: Beta blockers may precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud disease; use with caution and monitor for progression of arterial obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Labetalol may be effective in lowering blood pressure and relieving symptoms in patients with pheochromocytoma; however, patients may experience paradoxical hypertensive responses due to inadequate alpha-1 blockade (Manger 2002; Mazza 2014). Adequate alpha-1 blockade should be initiated prior to use of any beta-blocker in this setting; use with caution in patients with pheochromocytoma or consider alternative therapy. If possible, obtain diagnostic tests for pheochromocytoma prior to use since labetalol may spuriously cause falsely elevated levels of plasma catecholamine and urinary metanephrine (Bravo 2002; MacCarthy 1983).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness. Although the risk is small, labetalol may cause or exacerbate CNS depression; however, the use of beta-blockers should not be withheld if benefit exceeds this risk (Verbeek 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Beta blockers may mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299562\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186169\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9540&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Apraclonidine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives. <b> Exceptions: </b>Nicergoline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and beta-blockers if possible. If coadministration is necessary, patients should have overnight continuous ECG monitoring conducted after the first dose of fingolimod. Monitor patients for bradycardia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Beta-Blockers may enhance the hypoglycemic effect of Insulins. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Anilidopiperidine): May enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.<b> Exceptions: </b>Rifabutin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186200\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Labetalol serum concentrations may be increased if taken with food. Management: Administer with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186172\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186187\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in some animal reproduction studies. Labetalol crosses the placenta and can be detected in cord blood and infant serum after delivery (Haraldsson 1989; Rogers 1990). Fetal/neonatal bradycardia, hypoglycemia, hypotension, and/or respiratory depression have been observed following in utero exposure to labetalol. Reduced birth weight has also been observed following in utero exposure to beta-blockers as a class; adequate facilities for monitoring infants at birth is generally recommended.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated chronic maternal hypertension and preeclampsia are also associated with adverse events in the fetus, infant, and mother. Oral labetalol is considered an appropriate agent for the treatment of chronic hypertension in pregnancy (ACOG 2013; Magee 2014). Intravenous labetalol is recommended for use in the management of acute onset, severe hypertension (systolic BP &ge;160 mm Hg or diastolic BP &ge;110 mm Hg) with preeclampsia or eclampsia in pregnant and postpartum women. In general, avoid use of labetalol in women with asthma or heart failure (ACOG 2015; Magee 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186188\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Labetalol is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">The relative infant dose (RID) of labetalol is 3.6% when calculated using the highest breast milk concentration located and compared to an infant therapeutic dose of 3 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10%; when an RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Using the highest milk concentration (0.71 mcg/mL), the estimated daily infant dose via breast milk is 0.1065 mg/kg/day. This milk concentration was obtained following maternal administration of oral labetalol 300 mg twice daily (Mirpuri 2008). Milk concentrations have not been found to correspond to maternal serum concentrations (Lunell 1985; Michael 1979). Peak milk concentrations are noted to occur 1 to 3 hours after the maternal dose (Lunell 1985).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Asymptomatic bradycardia was observed in a preterm infant exclusively breastfed following maternal use of labetalol (Mirpuri 2008). Nipple pain and Raynaud phenomenon of the nipple has been associated with labetalol in case reports (Rolfes 2014). Some guidelines consider labetalol to be generally acceptable for use in breastfeeding women (Magee 2014). The manufacturer recommends that caution be exercised when administering labetalol to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186174\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, standing and sitting/supine, pulse, cardiac monitor and blood pressure monitor recommended for IV administration; consult individual institutional policies and procedures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186163\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks alpha<sub>1</sub>-, beta<sub>1</sub>-, and beta<sub>2</sub>-adrenergic receptor sites; elevated renins are reduced. The ratios of alpha- to beta-blockade differ depending on the route of administration estimated to be 1:3 (oral) and 1:7 (IV) (Goa 1989).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186183\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Oral: 20 minutes to 2 hours (McNeil 1984); IV: Within 5 minutes (Goa 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Oral: 2 to 4 hours; IV: 5 to 15 minutes (Goa 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Blood pressure response:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 8 to 12 hours (dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Average: 16 to 18 hours (dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Apparent V<sub>d</sub>: Adults: 2.5 to 15.7 L/kg (Goa 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, primarily via glucuronide conjugation; extensive first-pass effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: 25%; increased with liver disease, elderly, and concurrent cimetidine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Oral: 6 to 8 hours; IV: ~5.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Oral: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (55% to 60% as glucuronide conjugates, &lt;5% as unchanged drug [Goa 1989]); feces (12% to 27% as metabolites) (Goa 1989)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186186\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Labetalol HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (20 mL): $7.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Labetalol HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (5 mL): $5.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/10 mL (10 mL): $8.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Labetalol HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $56.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $113.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $114.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038665\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Albetol (FI);</li>\n      <li>Biascor (AR, PY);</li>\n      <li>Blocamine (AR);</li>\n      <li>Chenday (TW);</li>\n      <li>Hybloc (NZ);</li>\n      <li>Ipolab (IT);</li>\n      <li>Labecard (BD);</li>\n      <li>Labedin (TW);</li>\n      <li>Labesin (KR);</li>\n      <li>Labesol (LK);</li>\n      <li>Labeta (BD);</li>\n      <li>Lamitol (HR);</li>\n      <li>Normadate (IN);</li>\n      <li>Presolol (AU, TW);</li>\n      <li>Pressocard (PL);</li>\n      <li>Trandate (AE, AT, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CH, CI, CL, CY, CZ, DK, EE, EG, ES, ET, FR, GB, GH, GM, GN, GR, GY, HK, HN, HU, IE, IL, IQ, IR, IS, IT, JM, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PT, QA, SA, SC, SD, SE, SG, SI, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Trantalol (MY, SG);</li>\n      <li>Xin Yu Sen (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adams HP Jr, del Zoppo G, Alberts MJ, et al, &quot;Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology Affirms the Value of This Guideline as an Educational Tool for Neurologists,&quot; <i>Stroke</i>, 2007, 38(5):1655-711.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/17431204/pubmed\" target=\"_blank\" id=\"17431204\">17431204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25611642\"></a>American College of Obstetricians and Gynecologists (ACOG). Committee opinion no. 623: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. <i>Obstet Gynecol</i>. 2015;125(2):521-525. doi: 10.1097/01.AOG.0000460762.59152.d7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/25611642/pubmed\" target=\"_blank\" id=\"25611642\">25611642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG); Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/24150027/pubmed\" target=\"_blank\" id=\"24150027\">24150027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2011, 123(21):2434-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/21518977/pubmed\" target=\"_blank\" id=\"21518977\">21518977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo; <i>Br J Dermatol</i>, 2008, 158(6):1299-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/18410416/pubmed\" target=\"_blank\" id=\"18410416\">18410416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bravo EL. Pheochromocytoma. <i>Cardiol Rev</i>. 2002;10(1):44-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/11790269/pubmed\" target=\"_blank\" id=\"11790269\">11790269</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Breckenridge A, Orme M, Serlin MJ, et al &ldquo;Labetalol in Essential Hypertension,&rdquo; <i>Br J Clin Pharmacol</i>, 1982, (1 Suppl):37-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6124264/pubmed\" target=\"_blank\" id=\"6124264\">6124264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cumming AM, Brown JJ, Lever AF, et al, &ldquo;Treatment of Severe Hypertension by Repeated Bolus Injections of Labetalol,&rdquo; <i>Br J Clin Pharmacol</i>, 1979, 8(Suppl 2):199-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/393288/pubmed\" target=\"_blank\" id=\"393288\">393288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dahlof B, Devereux RB, Kjeldsen SE, et al; Life Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. <i>Lancet</i>. 2002;359(9311):995-1003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/11937178/pubmed\" target=\"_blank\" id=\"11937178\">11937178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erstad BL and Barletta JF, &ldquo;Treatment of Hypertension in the Perioperative Patient,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(1):66-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/10669188/pubmed\" target=\"_blank\" id=\"10669188\">10669188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goa KL, Benfield P, Sorkin EM. Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. <i>Drugs</i>. 1989;37(5):583-627.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2663413/pubmed\" target=\"_blank\" id=\"2663413\">2663413</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haraldsson A, Geven W. Half-life of maternal labetalol in a premature infant. <i>Pharm Weekbl Sci</i>. 1989;11(6):229-231.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2616255/pubmed\" target=\"_blank\" id=\"2616255\">2616255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jauch EC, Cucchiara B, Adeoye O, et al, &ldquo;Part 11: Adult Stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):818-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/20956227/pubmed\" target=\"_blank\" id=\"20956227\">20956227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jauch EC, Saver JL, Adams HP Jr, et al, &ldquo;Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,&rdquo; <i>Stroke</i>, 2013, 44(3):870-947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/23370205/pubmed\" target=\"_blank\" id=\"23370205\">23370205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Labetalol hydrochloride [prescribing information]. Princeton, NJ: BluePoint Laboratories; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Labetalol Carpuject [prescribing information]. Lake Forest, IL: Hospira Inc; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo; <i>Drug Saf</i>, 1995, 12(5):299-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/7669259/pubmed\" target=\"_blank\" id=\"7669259\">7669259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18250979\"></a>Liu-Deryke X, Janisse J, Coplin WM, Parker D Jr, Norris G, Rhoney DH. A comparison of nicardipine and labetalol for acute hypertension management following stroke. <i>Neurocrit Care</i>. 2008;9(2):167-176.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/18250979/pubmed\" target=\"_blank\" id=\"18250979\">18250979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunell NO, Kulas J, and Rane A, &quot;Transfer of Labetalol Into Amniotic Fluid and Breast Milk in Lactating Women,&quot; <i>Eur J Clin Pharmacol</i>, 1985, 28(5):597-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/4043203 /pubmed\" target=\"_blank\" id=\"4043203 \">4043203 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. <i>Pharmacotherapy</i>. 1983;3(4):193-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6310529/pubmed\" target=\"_blank\" id=\"6310529\">6310529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magee LA, Pels A, Helewa M, et al; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. <i>J Obstet Gynaecol Can</i>. 2014;36(5):416-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/24927294/pubmed\" target=\"_blank\" id=\"24927294\">24927294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manger WM, Gifford RW. Pheochromocytoma. <i>J Clin Hypertens (Greenwich)</i>. 2002;4(1):62-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/11821644/pubmed\" target=\"_blank\" id=\"11821644\">11821644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE and Rivera R. Hypertensive emergencies: an update. <i>Curr Opin Crit Care</i>. 2011;17(6):569-580.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/21986463/pubmed\" target=\"_blank\" id=\"21986463\">21986463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE and Varon J. Hypertensive crises: challenges and management. <i>Chest. 2007;</i>131(6);1949-1962.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/17565029/pubmed\" target=\"_blank\" id=\"17565029\">17565029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maronide RF, Robinson D, Vlachakis ND, et al, &ldquo;Study of Single and Multiple Dose Pharmacokinetic/Pharmacodynamic Modeling of the Antihypertensive Effects of Labetalol,&rdquo; <i>Am J Med</i>, 1983, 75(4A):40-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6356898/pubmed\" target=\"_blank\" id=\"6356898\">6356898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mazza A, Armigliato M, Marzola MC, et al. Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features. <i>Endocrine</i>. 2014;45(3):469-478.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/23817839/pubmed\" target=\"_blank\" id=\"23817839\">23817839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McNeil JJ, Louis WJ. Clinical pharmacokinetics of labetalol. <i>Clin Pharmacokinet</i>. 1984;9(2):157-167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6370541/pubmed\" target=\"_blank\" id=\"6370541\">6370541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Michael CA, &quot;The Evaluation of Labetalol in the Treatment of Hypertension Complicating Pregnancy,&quot; <i>Br J Clin Pharmacol</i>, 1982, 13(1 Suppl):127S-131S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/7093096/pubmed\" target=\"_blank\" id=\"7093096\">7093096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirpuri J, Patel H, Rhee D, et al. AFMR Southern Regional Meeting Abstracts. What's mom on? A case of bradycardia in a premature infant on breast milk. <i>J Investig Med</i>. 2008;56(1):409.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17967691\"></a>Mocco J, Rose JC, Komotar RJ, Mayer SA. Blood pressure management in patients with intracerebral and subarachnoid hemorrhage. <i>Neurosurg Clin N Am</i>. 2006;17(suppl 1):25-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/17967691/pubmed\" target=\"_blank\" id=\"17967691\">17967691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute (NHLBI). Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines, 2011, National Institutes of Health. <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>. Accessed March 16, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program (NHBPEP) Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo; <i>Pediatrics</i>, 2004, 114 (2 Suppl):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8439694\"></a>Patel RV, Kertland HR, Jahns BE, Zarowitz BJ, Mlynarek ME, Fagan SC. Labetalol: response and safety in critically ill hemorrhagic stroke patients. <i>Ann Pharmacother</i>. 1993;27(2):180-181.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/8439694/pubmed\" target=\"_blank\" id=\"8439694\">8439694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rogers RC, Sibai BM, Whybrew WD. Labetalol pharmacokinetics in pregnancy-induced hypertension. <i>Am J Obstet Gynecol</i>. 1990;162(2):362-366.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/2309815/pubmed\" target=\"_blank\" id=\"2309815\">2309815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rolfes L, de Swart-Ruijter I, van Hunsel F. Labetalol for hypertension during pregnancy and nipple pain. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2014;182:254-255.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/25445109 /pubmed\" target=\"_blank\" id=\"25445109 \">25445109 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo; <i>N Eng J Med</i>, 2005, 352(18):1899-1912.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/15872205/pubmed\" target=\"_blank\" id=\"15872205\">15872205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas CA, Moffett BS, Wagner JL, et al. Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. <i>Pediatr Crit Care Med</i>, 2011;12(1):28-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/20495503/pubmed\" target=\"_blank\" id=\"20495503\">20495503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trandate (labetalol) [prescribing information]. San Diego, CA: Prometheus Laboratories Inc; November 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo; <i>BMJ</i>, 1998, 317(7160):713-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/9732338/pubmed\" target=\"_blank\" id=\"9732338\">9732338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verbeek DE, van Riezen J, de Boer RA, van Melle JP, de Jonge P. A review on the putative association between beta-blockers and depression. <i>Heart Fail Clin</i>. 2011;7(1):89-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/21109212/pubmed\" target=\"_blank\" id=\"21109212\">21109212</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22528277\"></a>Woloszyn AV, McAllen KJ, Figueroa BE, DeShane RS, Barletta JF. Retrospective evaluation of nicardipine versus labetalol for blood pressure control in aneurysmal subarachnoid hemorrhage. <i>Neurocrit Care</i>. 2012;16(3):376-380. doi: 10.1007/s12028-012-9700-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/22528277/pubmed\" target=\"_blank\" id=\"22528277\">22528277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yuen PH, Taddei CR, Wyka BE, Chaudry IA. Compatibility and stability of labetalol hydrochloride in commonly used intravenous solutions. <i>Am J Hosp Pharm</i>. 1983;40(6):1007-1009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/labetalol-drug-information/abstract-text/6869384/pubmed\" target=\"_blank\" id=\"6869384\">6869384</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9540 Version 227.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F186205\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F186206\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F186247\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F186209\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F186227\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F186210\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F186211\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F186212\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F186176\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F186160\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F186180\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14472668\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472669\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F186179\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726710\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F186256\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F186167\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F186184\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F186164\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299562\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F186169\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F186200\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F186172\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F186187\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F186188\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F186174\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F186163\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F186183\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F186186\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038665\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9540|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=labetalol-patient-drug-information\" class=\"drug drug_patient\">Labetalol: Patient drug information</a></li><li><a href=\"topic.htm?path=labetalol-pediatric-drug-information\" class=\"drug drug_pediatric\">Labetalol: Pediatric drug information</a></li></ul></div></div>","javascript":null}